Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study
- 2 December 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (7) , 2550-2555
Abstract
Objectives: Nintedanib is an inhibitor of tyrosine kinases that has been shown to slow the progression of interstitial lung disease (ILD), including ILD associated with SSc. The aim of this study was to explore the effect of nintedanib on cardiomyopathy associated with systemic sclerosis (SSc). Methods: Twenty consecutively hospitalized patients with SSc-ILD were enrolled and prospectively followed. The rate of change at 6 months in cardiac magnetic resonance (CMR) parametric mapping, including myocardial extracellular volume, was primarily evaluated. Other endpoints included changes in CMR functional parameters, echocardiographic parameters, modified Rodnan skin score, serum biomarkers and pulmonary function test. Results: Nintedanib was administered in 10 patients, whereas the other 10 were treated without nintedanib or watched, according to ILD severity and progression. Baseline values of CMR parametric mapping were not different between the two groups. The rate of change at 6 months in myocardial extracellular volume was highly different, almost divergent, between the nintedanib group and the control group (−1.62% vs +2.00%, P = 0.0001). Among other endpoints, the change in right ventricular ejection fraction was significantly different between the two groups (P = 0.02), with a preferential change in the nintedanib group. Conclusion: Our data indicate beneficial signals of nintedanib on cardiomyopathy associated with SSc. The anti-fibrotic effect of nintedanib might not be limited to the lung.Keywords
Funding Information
- GlaxoSmithKline
- Taiju Life Social Welfare Foundation
This publication has 20 references indexed in Scilit:
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseNew England Journal of Medicine, 2019
- Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertensionCardiovascular Research, 2018
- Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosisAnnals of the Rheumatic Diseases, 2017
- Update of EULAR recommendations for the treatment of systemic sclerosisAnnals of the Rheumatic Diseases, 2017
- Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosisRheumatology, 2017
- Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic SclerosisJournal of Scleroderma and Related Disorders, 2017
- Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysisJournal of Cardiovascular Magnetic Resonance, 2016
- Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis – a clinical study using myocardial T1-mapping and extracellular volume quantificationJournal of Cardiovascular Magnetic Resonance, 2014
- Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung FibrosisThe Journal of Pharmacology and Experimental Therapeutics, 2014
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2013